# FIRST REGULAR NATIONAL REPORT ON THE IMPLEMENTATION OF THE CARTAGENA PROTOCOL ON BIOSAFETY

#### Origin of report

| Party:  | Portugal   |
|---|--|
| Contact officer for report                              |  |
| Name and title of contact officer:                      | Maria do Carmo Palma<br>Head of Unit<br>Environmental Risks and Emergencies Unit   |
| Mailing address:  | Portuguese Environment Agency Ministry of Environment, Spatial Planning and Regional Development Rua da Murgueira, 9/9A – Zambujal Apartado 7585 2611-865 Amadora PORTUGAL |
| Telephone:  | +351-21-4728368  |
| Fax:  | +351-21-4728231  |
| E-mail:   | carmo.figueira@apambiente.pt   |
| Submission  |  |
| Signature of officer responsible for submitting report: |  |
| Date of submission:                                     |  |
| Time period covered by this report:                     | Between entry into force of Cartagena Protocol on 11 September 2003 and 31 August 2007   |

Please provide summary information on the process by which this report has been prepared, including information on the types of stakeholders who have been actively involved in its preparation and on material which was used as a basis for the report:

This report was mainly prepared by the Portuguese Environment Agency, which is the Portuguese Competent Authority for the Cartagena Protocol on Biosafety. In addition, other relevant national authorities were also consulted for this purpose.

This report updates the information submitted on the interim implementation report presented in 2005. The interim report was written based on publicly accessible information on relevant legislation and implementation.

1. Several articles of the Protocol require that information be provided to the Biosafety Clearing-House (see the list below). For your Government, if there are cases where relevant information exists but has not been provided to the Biosafety Clearing-House (BCH), describe any obstacles or impediments encountered regarding provision of that information (note: To answer this question, please check the BCH to determine the current status of your country's information submissions relative to the list of required information below. If you do not have access to the BCH, contact the Secretariat for a summary):

As a member of the EU, the European legislation on genetically modified organism (GMO) which has been in place since the early 1990s, is either directly applicable in Portugal or was been implemented on Portuguese legislation.

In this regard, relevant information concerning the EU system has been provided. In addition Portugal has submitted information to the Biosafety Clearing House mainly relating to the following issues:

- Contacts for the competent national authority and national focal point
- Existing national legislation regulating the authorisation of LMOs intent for release into the environment, both for experimental or commercial purposes
- Existing national legislation for the implementation of the Protocol

With respect of further information requirements of the protocol it is to be expected that the information will be provided step by step in the near future.

2. Please provide an overview of information that is required to be provided to the Biosafety Clearing-House:

| Type of information   | Information exists and is being provided to the Biosafety Clearing-House | Information exists but is not yet provided to the Biosafety Clearing-House | Information<br>does not exist<br>/not<br>applicable |
|---|--|--|---|
| a) Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20.3(a)) | X  |  |   |
| b) National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11.5);  | X  |  |   |
| c) Bilateral, multilateral and regional agreements and arrangements (Articles 14.2, 20.3(b), and 24.1);   |  |  | X   |
| d) Contact details for competent national authorities (Articles 19.2 and 19.3), national focal points (Articles 19.1 and 19.3), and emergency contacts (Article 17.2 and 17.3(e));                    | X  |  |   |

| e) In cases of multiple competent national authorities, responsibilities for each (Articles 19.2 and 19.3);   |  |  | X   |
|---|--|--|---|
| f) Reports submitted by the Parties on the operation of the Protocol (Article 20.3(e));   |  | X  |   |
| g) Occurrence of unintentional transboundary<br>movements that are likely to have significant<br>adverse effects on biological diversity<br>(Article 17.1);   |  |  | X   |
| Type of information   | Information exists and is being provided to the Biosafety Clearing-House | Information exists but is not yet provided to the Biosafety Clearing-House | Information<br>does not exist<br>/not<br>applicable |
| h) Illegal transboundary movements of LMOs (Article 25.3);  |  |  | X   |
| i) Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10.3 and 20.3(d));                                       | X  |  |   |
| j) Information on the application of domestic regulations to specific imports of LMOs (Article 14.4);   |  |  | X   |
| k) Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11.1);   |  |  | X   |
| 1) Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11.4) or in accordance with annex III (Article 11.6) (requirement of Article 20.3(d)) | X  |  |   |
| m) Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11.6)   | X  |  |   |
| n) Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12.1);   |  |  | X   |
| o) LMOs granted exemption status by each Party (Article 13.1)   |  |  | X   |

| p) Cases where intentional transboundary<br>movement may take place at the same time as the<br>movement is notified to the Party of import<br>(Article 13.1);                       |   | X |
|---|---|---|
| q) Summaries of risk assessments or<br>environmental reviews of LMOs generated by<br>regulatory processes and relevant information<br>regarding products thereof (Article 20.3(c)). | X |   |

## Article 2 – General provisions

| 3. Has your country introduced the necessary legal, administrative and other measures for implementation of the Protocol? (Article 2.1) |   |  |
|---|---|--|
| a) full domestic regulatory framework in place (please give details below)  | X |  |
| b) some measures introduced (please give details below)   |   |  |
| c) no measures yet taken  |   |  |

4. Please provide further details about your response to the above question, as well as description of your country's experiences and progress in implementing Article 2, including any obstacles or impediments encountered:

As a member of the European Union, Portugal is subject to EU regulations on GMOs.

At EU level, it has been developed a comprehensive legal framework on GMOs, which also addresses handling, transport, packaging and identification requirements. Of the recently adopted legal acts, the following are of direct relevance to implementation of Cartagena Protocol:

- Regulation (EC) 1946/2003 of 15<sup>th</sup> July 2003 on transboundary movements of genetically modified organisms;
- Regulation (EC) 1829/2003 of 22<sup>nd</sup> September 2003 on genetically modified food and feed; and
- Regulation (EC) 1830/2003 of 22<sup>nd</sup> September 2003 concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms.
- Regulation (EC) No 641/2004 of 6<sup>th</sup> April 2004 on detailed rules for the implementation of Regulation (EC) No 1829/2003 as regards the application for the authorisation of new genetically modified food and feed, the notification of existing products and adventitious or technically unavoidable presence of genetically modified material which has benefited from a favourable risk evaluation.

Regulations 1829/2003 and 1830/2003 have been linked to the Portuguese GMO law where penalties can be found.

Directive 2001/18/EC on the Deliberate Release of Genetically Modified Organisms into the Environment has been incorporated into Portuguese law by the Decree law no. 72/2003, of 10<sup>th</sup> April, which regulates the deliberate release and placing on the market of GMOs.

Regarding the contained use of genetically modified micro-organisms the Directive 90/219/EC of 23<sup>rd</sup> April 1990 on the contained use of genetically modified micro-organisms and Directive 98/81/EC of 26<sup>th</sup> October 1998 amending Directive 90/219/EEC on the contained use of genetically modified micro-organisms, are also incorporated into Portuguese law by the Decree law no. 2/2001, of 4<sup>th</sup> January, which

regulates the contained use of genetically modified micro-organisms.

Decree-law no. 164/2004, of 3<sup>rd</sup> July, that modifies the Decree-law no. 72/2003, of 10th April in accordance with Regulation 1829/2003 of the European Parliament and the Council of 22<sup>nd</sup> September 2003 on genetically modified food and feed and Regulation no. 1830/2003 of the European Parliament and of the Council of 22<sup>nd</sup> September 2003 concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms and amending Directive 2001/18/EC.

Decree-law no. 168/2004, of 7<sup>th</sup> July, that executes Regulation no. 1830/2003 of the European Parliament and the Council of 22<sup>nd</sup> September 2003 concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms and amending Directive 2001/18/EC.

Decree law no. 102/2005, of 23<sup>rd</sup> July, that executes Regulation no. 1829/2003 of the European Parliament and the Council of 22<sup>nd</sup> September 2003 on genetically modified food and feed.

Decree-law no. 160/2005, of 21<sup>st</sup> September, that introduces coexistence measures of genetically modified crops with conventional and organic farming.

Decree-law no. 36/2006, of 20<sup>th</sup> February, it assures the execution and guarantees the fulfilment, in the national jurisprudence, of the obligations for the Portuguese State of the Regulation No 1946/2003 of the European Parliament and of the Council, of 15<sup>th</sup> July 2003, on transboundary movements of genetically modified organisms.

The Instrument of Acceptance of the Cartagena Protocol on Biosafety to the Convention on Biological Diversity was deposited by Portugal on 30<sup>th</sup> September 2004.

Articles 7 to 10 and 12: The advance informed agreement procedure
See question 1 regarding provision of information to the Biosafety Clearing-House.

| . Were you a Party of import during this reporting period?   |   |  |
|--|---|--|
| a) yes   | X |  |
| b) no  |   |  |
| 6. Were you a Party of export during this reporting period?  |   |  |
| a) yes   |   |  |
| b) no  | X |  |
| 7. Is there a legal requirement for the accuracy of information provided by exporters 1/ under the jurisdiction of your country? (Article 8.2) |   |  |
| a) yes   | X |  |
| b) not yet, but under development  |   |  |
| c) no  |   |  |
| d) not applicable – not a Party of export  |   |  |

<sup>1/</sup> The use of terms in the questions follows the meanings accorded to them under Article 3 of the Protocol.

| 8. If you were a Party of export during this reporting period, did you request any Par review a decision it had made under Article 10 on the grounds specified in Article 12.   |                      |  |
|---|----------------------|--|
| a) yes (please give details below)  |                      |  |
| b) not yet, but under development   |                      |  |
| c) no   |                      |  |
| d) not applicable – not a Party of export   | X                    |  |
| 9. Did your country take decisions regarding import under domestic regulatory fram by Article 9.2(c).   | eworks as allowed    |  |
| a) yes  |                      |  |
| b) no   |                      |  |
| c) not applicable – no decisions taken during the reporting period  | X                    |  |
| 10. If your country has been a Party of export of LMOs intended for release into the enth the reporting period, please describe your experiences and progress in implementing A 12, including any obstacles or impediments encountered:                                     |                      |  |
| Not applicable - Portugal has not been a Party of export of LMOs intended environment.  | for release into the |  |
| 11. If your country has taken decisions on import of LMOs intended for release into the environment during the reporting period, please describe your experiences and progress in implementing Articles 7 to 10 and 12, including any obstacles or impediments encountered: |                      |  |
| Portugal implemented EU and domestic legislation regulating the authorisation of LMOs intended for release into the environment, both for experimental or commercial purposes. The legislation is in line with the provisions of the Protocol.                              |                      |  |
| Until the present date Portugal has not taken decisions on import of LMO intended for release into the environment.   |                      |  |
| However, under the EU domestic legal framework (EU Dir. 2001/18 and Reg. 1829/2003), several decisions have been taken. This framework is compatible with the provisions of the Protocol.   |                      |  |
| Decisions on releases in the form of field trials are made at the national level. Decisions on field trials are always based on an application in accordance with the provisions of articles 5-11.  |                      |  |
| Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing   |                      |  |
| See question 1 regarding provision of information to the Biosafety Clearing-House.  |                      |  |
| 12. Is there a legal requirement for the accuracy of information provided by the applicant with respect to the domestic use of a living modified organism that may be subject to transboundary movement for direct use as food or feed, or for processing? (Article 11.2)   |                      |  |
| a) yes  | X                    |  |
| b) not yet, but under development   |                      |  |
|   |                      |  |

d) not applicable (please give details below)

13. Has your country indicated its needs for financial and technical assistance and capacity-building in respect of living modified organisms intended for direct use as food or feed, or for processing? (Article 11.9)

| a) yes (please give details below) |   |
|------------------------------------|---|
| b) no                              |   |
| c) not relevant                    | X |

14. Did your country take decisions regarding import under domestic regulatory frameworks as allowed by Article 11.4?

| a) yes   |   |
|--|---|
| b) no  |   |
| c) not applicable – no decisions taken during the reporting period | X |

15. If your country has been a Party of export of LMOs intended for direct use for food or feed, or for processing, during the reporting period, please describe your experiences and progress in implementing Article 11, including any obstacles or impediments encountered:

Not applicable. Portugal has not been a Party of export of LMOs intended for direct use for food or feed, or for processing, during the reporting period.

According to EU legislation (Directive no. 2001/18/EC and Regulation no. 1829/2003) all decisions concerning imports for placing on the market, including release into the environment, are taken at the EU level.

Regarding exports, EU Regulation no. 1946/2003 establishes the obligations of exporters of GMO-FFPs from an EU member-state to a third country. The exporter must comply with the decision of the importing country regarding GMO-FFPs.

16. If your country has been a Party of import of LMOs intended for direct use for food or feed, or for processing, during the reporting period, please describe your experiences and progress in implementing Article 11, including any obstacles or impediments encountered:

Being part of the EU, Portugal follows the comprehensive legal framework on GMOs developed at EU level, which also addresses the import of LMOs intended for direct use for food or feed, or for processing. The EC has declared with reference to Article 14.4 Cartagena Protocol that it relies on its existing legislative framework for intentional movements of GMOs within the Community and for imports of GMOs into the EC.

All the recently approved EC Regulations regarding GMOs intended for direct use for food or feed, transboundary movements, and the traceability and labelling of GMOs, as well as the traceability of products containing GMOs are directly applicable.

Decisions within the EU legal framework regarding the import of LMOs intended for direct use for food or feed, or for processing, apply within the entire EU. For further details regarding the decisions taken, please refer to the comprehensive information given by the EU in the report of the EC.

#### Article 13 – Simplified procedure

See question 1 regarding provision of information to the Biosafety Clearing-House.

| 17. Have you applied the simplified procedure during the reporting period? |        |  |
|--|--------|--|
|  | a) yes |  |

18. If your country has used the simplified procedure during the reporting period, or if you have been unable to do so for some reason, please describe your experiences in implementing Article 13, including any obstacles or impediments encountered:

Portugal has not applied the simplified procedure during the reporting period.

Article 14 – Bilateral, regional and multilateral agreements and arrangements See question 1 regarding provision of information to the Biosafety Clearing-House.

| 19. Has your country entered into any bilateral, regional or multilateral agreements or arrangements? |   |  |
|---|---|--|
| a) yes  |   |  |
| b) no   | X |  |

20. If your country has entered into bilateral, regional or multilateral agreements or arrangements, or if you have been unable to do so for some reason, describe your experiences in implementing Article 14 during the reporting period, including any obstacles or impediments encountered:

Portugal has not entered into bilateral, regional or multilateral agreements or arrangements, during the reporting period.

## Articles 15 and 16 – Risk assessment and risk management

| carried out for all |
|---------------------|
|                     |
|                     |
| X                   |
| ?                   |
|                     |
|                     |
|                     |
| X                   |
| e the notifier to   |
|                     |
|                     |
|                     |
| X                   |
|                     |

| 24. Has your country established and maintained appropriate mechanisms, measures a regulate, manage and control risks identified in the risk assessment provisions of the P 16.1)   |                    |
|---|--------------------|
| a) yes – fully established  | X                  |
| b) not yet, but under development or partially established (please give further details below)  |                    |
| c) no   |                    |
| 25. Has your country adopted appropriate measures to prevent unintentional transbour of living modified organisms? (Article 16.3)   | ndary movements    |
| a) yes – fully adopted  | X                  |
| b) not yet, but under development or partially adopted (please give further details below)  |                    |
| c) no   |                    |
| 26. Does your country endeavour to ensure that any living modified organism, whether locally developed, undergoes an appropriate period of observation commensurate with generation time before it is put to its intended use? (Article 16.4) |                    |
| a) yes – in all cases   | X                  |
| b) yes – in some cases (please give further details below)  |                    |
| c) no (please give further details below)   |                    |
| d) not applicable (please give further details below)   |                    |
| 27. Has your country cooperated with others for the purposes specified in Article 16.5  | ?                  |
| a) yes (please give further details below)  | X                  |
| b) no (please give further details below)   |                    |
| 28. Please provide further details about your responses to the above questions, as well your country's experiences and progress in implementing Articles 15 and 16, including impediments encountered:  | g any obstacles or |
| ELL logislation forescent that all notifications shall contain a might assessment   | 41:                |

EU legislation foreseen that all notifications shall contain a risk assessment as outlined in EU Directive 2001/18/EC. This implies an assessment of the LMO on a lifetime basis. Risk assessments are to be evaluated by all member-states. The European Food Safety Authority (EFSA) and the competent authorities of the Member States evaluate risk assessments contained in the notifications submitted under EU Regulation 1829/2003.

The aim of the environmental risk assessment is, on a case by case basis, to identify and evaluate potential adverse effects of the GMO, both direct and indirect, immediate or delayed, on human health and the environment.

This assessments conducted on a "case by case" basis in accordance with the procedures laid down in EU and national legislation, are carried out firstly by the notifier and then evaluated by the national scientific advisory technical bodies that support decisions taken by ministries responsible for GMO's management.

Although Portugal has not yet had to perform LMO risk assessments under the requirements of the Protocol, it has experience with the risk assessment procedures required, as these are very similar to the risk assessment performed for deliberate release and placing on the market under EU legislation.

Please see EC Report for further information on the procedures at EU level.

Article 17 – Unintentional transboundary movements and emergency measures See question 1 regarding provision of information to the Biosafety Clearing-House.

| 29. During the reporting period, if there were any occurrences under your jurisdiction have led, to an unintentional transboundary movement of a living modified organism that had, significant adverse effects on the conservation and sustainable use of biolog taking also into account risks to human health in such States, did you immediately corpotentially affected States for the purposes specified in Article 17.4? | that had, or could ical diversity, |
|---|------------------------------------|
| a) yes – all relevant States immediately  |                                    |
| b) yes – partially consulted, or consultations were delayed (please clarify below)  |                                    |
| c) no – did not consult immediately (please clarify below)  |                                    |
| d) not applicable (no such occurrences)   | X                                  |
| 30. Please provide further details about your response to the above question, as well as description of your country's experiences in implementing Article 17, including any obstacles or impediments encountered:  |                                    |
| Not applicable.   |                                    |

# Article 18 – Handling, transport, packaging and identification

| 31. Has your country taken measures to require that living modified organisms that are subject to transboundary movement within the scope of the Protocol are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards? (Article 18.1)           |                      |
|--|----------------------|
| a) yes (please give details below)   | X                    |
| b) not yet, but under development  |                      |
| c) no  |                      |
| d) not applicable (please clarify below)   |                      |
| 32. Has your country taken measures to require that documentation accompanying liv organisms for direct use as food or feed, or for processing, clearly identifies that they modified organisms and are not intended for intentional introduction into the environn contact point for information? (Article 18.2(a)) | 'may contain' living |
| a) yes   | X                    |
| b) not yet, but under development  |                      |
| c) no  |                      |

| 33. Has your country taken measures to require that documentation accompanying living modified              |
|---|
| organisms that are destined for contained use clearly identifies them as living modified organisms and      |
| specifies any requirements for the safe handling, storage, transport and use, the contact point for further |
| information, including the name and address of the individual and institution to whom the living modified   |
| organisms are consigned? (Article 18.2(b))  |

| a) yes                            | X |
|-----------------------------------|---|
| b) not yet, but under development |   |
| c) no                             |   |

34. Has your country adopted measures to require that documentation accompanying living modified organisms that are intended for intentional introduction into the environment of the Party of import and any other living modified organisms within the scope of the Protocol, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter? (Article 18.2(c))

| a) yes                            | X |
|-----------------------------------|---|
| b) not yet, but under development |   |
| c) no                             |   |

35. Please provide further details about your responses to the above questions, as well as a description of your country's experiences and progress in implementing Article 18, including any obstacles or impediments encountered:

Portugal has incorporated into domestic legislation, measures concerning the requirements for handling, storage, packaging and transport and identification of LMOs and is implementing the measures and regulations approved at European Union level.

For further details please see EC Report.

Article 19 – Competent national authorities and national focal points

See question 1 regarding provision of information to the Biosafety Clearing-House.

*Article 20 – Information-sharing and the Biosafety Clearing-House* 

See question 1 regarding provision of information to the Biosafety Clearing-House.

36. In addition to the response to question 1, please describe any further details regarding your country's experiences and progress in implementing Article 20, including any obstacles or impediments encountered:

#### *Article 21 – Confidential information*

37. Does your country have procedures to protect confidential information received under the Protocol and that protect the confidentiality of such information in a manner no less favourable than its treatment of confidential information in connection with domestically produced living modified organisms? (Article 21.3)

| ,      |   |
|--------|---|
| a) yes | X |

| b) not yet, but under development  |  |
|--|--|
| c) no  |  |
| 38. If you were a Party of import during this reporting period, did you permit any not information submitted under the procedures of the Protocol or required by the Party of the advance informed agreement procedure that was to be treated as confidential? (Art  | f import as part of                    |
| a) yes   |  |
| If yes, please give number of cases  |  |
| b) no  |  |
| c) not applicable – not a Party of import / no such requests received  | X                                      |
| 39. If you answered yes to the previous question, please provide information on your including description of any impediments or difficulties encountered:   | experience                             |
|  |  |
| 40. If you were a Party of export during this reporting period, please describe any implementation of the requirements of Article 21:  |  |
| Not applicable – Portugal was not a Party of export during this reporting period.  |  |
| Article 22 – Capacity-building   |  |
| 41. If a developed country Party, during this reporting period has your country cooper development and/or strengthening of human resources and institutional capacities in burposes of the effective implementation of the Protocol in developing country Parties least developed and small island developing States among them, and in Parties with extransition? | oiosafety for the s, in particular the |
| a) yes (please give details below)   |  |
| b) no  | X                                      |
| c) not applicable – not a developed country Party  |  |
| 42. If yes to question 41, how has such cooperation taken place:   |  |
|  |  |
| 43. If a developing country Party, or Party with an economy in transition, during this your country contributed to the development and/or strengthening of human resources capacities in biosafety for the purposes of the effective implementation of the Protoco developing country Party or Party with an economy in transition?                                | and institutional                      |
| a) yes (please give details below)   | X                                      |
| b) no  |  |
| c) not applicable – not a developing country Party   |  |
| 44. If yes to question 43, how has such cooperation taken place:   |  |
| In 7 February 2007 was signed a Memorandum of Cooperation (MoC) to e   | enhance human and                      |

12

institutional capacities in Africa for the effective implementation of the Convention on Biological Diversity (CBD) and its Cartagena Protocol on Biosafety. This MoC was signed by the Minister of

Environment, Spatial Planning and Regional Development of the Government of Portugal, the Chief Executive Officer of the New Partnership for Africa's Development (NEPAD) and the Convention on Biological Diversity. This strategic partnership will promote capacity-building through training and exchange of experiences and best practices among the national focal points for the Convention, an its Cartagena Protocol on Biosafety. 45. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training in the proper and safe management of biotechnology to the extent that it is required for biosafety? a) yes – capacity-building needs fully met (please give details below) b) yes – capacity-building needs partially met (please give details below) c) no – capacity-building needs remain unmet (please give details below) d) no – we have no unmet capacity-building needs in this area e) not applicable – not a developing country Party or a Party with an economy X in transition 46. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training in the use of risk assessment and risk management for biosafety? a) yes – capacity-building needs fully met (please give details below) b) yes – capacity-building needs partially met (please give details below) c) no – capacity-building needs remain unmet (please give details below) d) no – we have no unmet capacity-building needs in this area e) not applicable – not a developing country Party or a Party with an economy X in transition 47. If a developing country Party or a Party with an economy in transition, have you benefited from cooperation for technical and scientific training for enhancement of technological and institutional capacities in biosafety? a) yes – capacity-building needs fully met (please give details below) b) yes – capacity-building needs partially met (please give details below) c) no – capacity-building needs remain unmet (please give details below) d) no – we have no unmet capacity-building needs in this area e) not applicable – not a developing country Party or a Party with an economy X in transition 48. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 22, including any obstacles or

13

impediments encountered:

#### *Article 23 – Public awareness and participation*

| 49. Does your country promote and facilitate public awareness, education and particip the safe transfer, handling and use of living modified organisms in relation to the conse sustainable use of biological diversity, taking also into account risks to human health? | ervation and    |
|--|-----------------|
| a) yes – significant extent  |                 |
| b) yes – limited extent  | X               |
| c) no  |                 |
| 50. If yes, do you cooperate with other States and international bodies?   |                 |
| a) yes – significant extent  |                 |
| b) yes – limited extent  | X               |
| c) no  |                 |
| 51. Does your country endeavour to ensure that public awareness and education encon information on living modified organisms identified in accordance with the Protocol th imported? (Article 23.1(b))   |                 |
| a) yes – fully   |                 |
| b) yes – limited extent  | X               |
| c) no  |                 |
| 52. Does your country, in accordance with its respective laws and regulations, consult decision-making process regarding living modified organisms and make the results of available to the public? (Article 23.2)   |                 |
| a) yes – fully   | X               |
| b) yes – limited extent  |                 |
| c) no  |                 |
| 53. Has your country informed its public about the means of public access to the Biosa House? (Article 23.3)   | afety Clearing- |
| a) yes – fully   | X               |
| b) yes – limited extent  |                 |
| c) no  |                 |
| 54. Please provide further details about your responses to the above questions, as well your country's experiences and progress in implementing Article 23, including any obs  | •               |

impediments encountered:

Portugal has put available in the website of the Portuguese Environment Agency information regarding GMO regulations, news, field trials, etc. This website is not yet fully developed but the BCH mechanism is described and a link to the central BCH is provided.

Moreover, Portugal is a Party to the Aarhus Convention on Access to information, public participation in decision-making and access to justice in environmental matters.

As foreseen by article 9 of Directive 2001/18/EC, Portugal has to consult the public on the proposed deliberate release. It has been laid down a time-period of 60 days maximum for the public express its opinion. The procedure defined for public information integrates the following actions:

- informing the mayors of the towns where the deliberate release is to take place;
- advertising in national newspapers;
- highlighting the public consultation and putting available the non-confidential part of the notification in the website of Portuguese Environmental Agency (www.iambiente.pt).

Afterwards, we also put available on the website, the decisions taken and a list of the field trials in place.

#### Article 24 – Non-Parties

See question 1 regarding provision of information to the Biosafety Clearing-House.

| 55. Have there been any transboundary movements of living modified organisms betwand a non-Party during the reporting period?  | veen your country |
|--|-------------------|
| a) yes   |                   |
| b) no  | X                 |
| 56. If there have been transboundary movements of living modified organisms between a non-Party, please provide information on your experience, including description of a difficulties encountered: | 2                 |
|  |                   |

#### Article 25 – Illegal transboundary movements

See question 1 regarding provision of information to the Biosafety Clearing-House.

| 57. Has your country adopted appropriate domestic measures to prevent and penalize, transboundary movements of living modified organisms carried out in contravention of measures? (Article 25.1)                  |              |
|--|--------------|
| a) yes   | X            |
| b) no  |              |
| 58. Have there been any illegal transboundary movements of living modified organism country during the reporting period?   | ms into your |
| a) yes   |              |
| b) no  | X            |
| 59. Please provide further details about your response to the above question, as well as description of your country's experiences in implementing Article 25, including any obstacles or impediments encountered: |              |

As an EU Member State, Portugal is obliged to adopt domestic measures to prevent and penalize illegal transboundary movements of GMOs. European legislation contains explicit obligations.

The main legal measures include:

- Article 33 of the EC Directive 2001/18 on the deliberate release into the environment of GMOs;
- Article 18 of Regulation no. 1946/2003 on transboundary movements of genetically modified organisms;
  - Article 45 of Regulation no. 1829/2003 on genetically modified food and feed.

Portuguese legislation on GMOs foresees penalties and sanctions for the previous situations.

However, in what concerns to Regulation no. 1946/2003, it was published a legal act that assures the execution and it guarantees the fulfilment, in the Portuguese jurisprudence, of the decurrently obligations of the Regulation which includes penalties to infringements of the provisions established.

#### *Article 26 – Socio-economic considerations*

| 60. If during this reporting period your country has taken a decision on import, did it take into account socio-economic considerations arising from the impact of living modified organisms on the conservation and sustainable use of biological diversity, especially with regard to the value of biological diversity to indigenous and local communities? (Article 26.1) |   |  |
|---|---|--|
| a) yes – significant extent   |   |  |
| b) yes – limited extent   |   |  |
| c) no   | X |  |
| d) not a Party of import  |   |  |
| 61. Has your country cooperated with other Parties on research and information exchange on any socio-<br>economic impacts of living modified organisms, especially on indigenous and local communities?<br>(Article 26.2)   |   |  |
| a) yes – significant extent   |   |  |
| b) yes – limited extent   |   |  |
| c) no   | X |  |
| (2) Place movide further details shout your manager to the should receive a small or description of   |   |  |

62. Please provide further details about your responses to the above questions, as well as description of your country's experiences and progress in implementing Article 26, including any obstacles or impediments encountered:

Socio-economic considerations have been relevant at Member State level for the question of co-existence. The European Commission has issued a Recommendation on 23<sup>rd</sup> July 2003 on guidelines for the development of national strategies and best practices to ensure the coexistence of genetically modified crops with conventional and organic farming. This non-binding Recommendation aims at ensuring that no form of agriculture be excluded in the EU and that consumers and producers are given a choice with regard to agricultural produce.

However, Member States are obliged to develop measures for coexistence, based on the guidelines provided by the European Commission. In this regard, Portugal adopted the Decree-law no. 160/2005, of 21<sup>st</sup> September, that introduce coexistence measures of genetically modified crops with conventional and organic farming, namely for transgenic maize (which is so far the only variety allowed for cultivation).

Please see EC report.

#### Article 28 – Financial mechanism and resources

| 63. Please indicate if, during the reporting period, your Government made financial resources available to other Parties or received financial resources from other Parties or financial institutions, for the purposes |   |  |
|---|---|--|
| of implementation of the Protocol.  |   |  |
| a) yes – made financial resources available to other Parties  |   |  |
| b) yes – received financial resources from other Parties or financial institutions  |   |  |
| c) both   |   |  |
| d) neither  | X |  |

64. Please provide further details about your response to the above question, as well as description of your country's experiences, including any obstacles or impediments encountered:

Not applicable.

#### Other information

65. Please use this box to provide any other information related to articles of the Protocol, questions in the reporting format, or other issues related to national implementation of the Protocol:

#### ANNEX

#### Portuguese legislative acts and measures

- 1. Decree law no. 2/2001, of  $4^{th}$  January, which regulates the contained use of genetically modified micro-organisms
- 2. Decree law no. 72/2003, of 10<sup>th</sup> April, which regulates the deliberate release and placing on the market of GMOs
- 3. Decree-law no. 164/2004, of 3<sup>rd</sup> July, that modifies the Decree-law no. 72/2003, of 10th April in accordance with Regulation no. 1829/2003 of the European Parliament and the Council of 22 September 2003 on genetically modified food and feed and Regulation no. 1830/2003 of the European Parliament and of the Council of 22 September 2003 concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms and amending Directive 2001/18/EC.
- 4. Decree-law no. 168/2004, of 7<sup>th</sup> July, that executes Regulation no. 1830/2003 of the European Parliament and the Council of 22 September 2003 concerning the traceability and labelling of genetically modified organisms and the traceability of food and feed products produced from genetically modified organisms and amending Directive 2001/18/EC
- 5. Decree law no. 102/2005, of 23<sup>rd</sup> July, that executes Regulation no. 1829/2003 of the European Parliament and the Council of 22 September 2003 on genetically modified food and feed
- 6. Decree-law no. 160/2005, of 21<sup>st</sup> September, that introduces coexistence measures of genetically modified crops with conventional and organic farming.
- 7. Decree-law no. 36/2006, of 20<sup>th</sup> February, it assures the execution and it guarantees the fulfilment, in the national jurisprudence, of the decurrent obligations for the Portuguese State of the Regulation No 1946/2003 of the European Parliament and of the Council, of 15<sup>th</sup> July 2003, on transboundary movements of genetically modified organisms

## Comments on reporting format

The wording of these questions is based on the Articles of the Protocol. Please provide information on any difficulties that you have encountered in interpreting the wording of these questions:

No difficulties have been encountered in interpreting the wording of these questions.